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Using a genetic, observational study as a strategy to
estimate the potential cost-effectiveness of pharmacological
CCR5 blockade in dialysis patients
Friso L.H. Muntinghea, Stefan Vegtera,b, Marion Verduijnc,
Elisabeth W. Boeschotend, Friedo W. Dekkerc, Gerjan Navisa
and Maarten Postmab
Background and objective Randomized clinical trials are
expensive and time consuming. Therefore, strategies are
needed to prioritise tracks for drug development. Genetic
association studies may provide such a strategy by
considering the differences between genotypes as a proxy
for a natural, lifelong, randomized at conception, clinical
trial. Previously an association with better survival was
found in dialysis patients with systemic inflammation
carrying a deletion variant of the CC-chemokine receptor 5
(CCR5). We hypothesized that in an analogous manner,
pharmacological CCR5 blockade could protect against
inflammation-driven mortality and estimated if such a
treatment would be cost-effective.
Methods A genetic screen and treat strategy was
modelled using a decision-analytic Markov model, in which
patients were screened for the CCR5 deletion 32
polymorphism and those with the wild type and systemic
inflammation were treated with pharmacological CCR5
blockers. Kidney transplantation and mortality rates were
calculated using patient level data. Extensive sensitivity
analyses were performed.
Results The cost-effectiveness of the genetic screen and
treat strategy was h18 557 per life year gained and h21 896
per quality-adjusted life years gained. Concordance
between the genetic association and pharmacological
effectiveness was a main driver of cost-effectiveness.
Sensitivity analyses showed that even a modest
effectiveness of pharmacological CCR5 blockade would
result in a treatment strategy that is good value for money.
Conclusion Pharmacological blockade of the CCR5
receptor in inflamed dialysis patients can be incorporated in a
potentially cost-effective screen and treat programme. These
findings provide formal rationale for clinical studies. This
study illustrates the potential of genetic association studies
for drug development, as a source of Mendelian randomized
evidence from an observational setting. Pharmacogenetics
and Genomics 21:417–425 c 2011 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
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Introduction
Pharmacological interventions that are of benefit in
nondialysis populations have thus far been disappointing
in dialysis patients, underscoring the need for novel
intervention strategies, specifically targeted at the
dialysis population [1,2]. However, development of novel
pharmacological approaches followed by randomized
clinical trials is expensive and time consuming, providing
an immense obstacle to the development and introduc-
tion of innovative approaches in patient care. Research
and development costs for a single approved cardiovas-
cular drug can reach hundreds of millions of dollars,
with most costs accrued in phase II and III trials [3].
Therefore, alternative strategies are urgently needed to
facilitate the multifaceted process from drug development
to introduction in clinical practice. Observational studies
using genetic variants might provide such a strategy [4].
Given the random assignment of alleles in gamete for-
mation, genetic variants can be considered to mimic the
randomization process of randomized clinical trials. Data
obtained through genetic association studies could there-
fore be considered a type of natural, lifelong, clinical trial,
with genetically different groups being randomized at
conception, hereby limiting confounding. This approach is
known as Mendelian randomization [5,6].
One of the main driving forces in the accelerated
atherosclerosis in patients with end-stage renal disease
(ESRD) is chronic inflammation [7]. This population
might therefore benefit from alternative therapies
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directed against the chronic inflammatory response. In
this inflammatory process chemokines and chemokine
receptors play an important role [8–10]. One of the
chemokine receptors involved is the CC-chemokine 5
receptor (CCR5). Animal data show that pharmacologic
intervention in the CCR5 chemokine pathway reduces
atherosclerosis [11–13]. The relevance of these findings
for humans is supported by genetic association studies on
the CCR5 deletion 32 (CCR5D32) polymorphism,
leading to functional CCR5 deficiency [14]. These
studies show that CCR5D32 is associated with better
outcome in different populations [15–18]. Previously, we
found that CCR5D32 was associated with protection
against mortality in a Dutch cohort of dialysis patients
characterized by inflammation and replicated these
findings in a Swedish cohort [19]. Taken together, these
data suggest that intervention-targeting inflammation, in
particular targeting the CCR5, may have the potential to
improve prognosis in ESRD [20].
Interestingly, pharmacological blockade of CCR5 is
feasible in human as it is applied in clinical practice for
treatment of human immunovirus (HIV) infection, which
increases the feasibility of development of CCR5
blockade as a treatment strategy for protection against
inflammation-driven atherosclerosis in ESRD [21].
In line with the above, genetic association data on long-
term outcome in patients with versus without CCR5D32
can be considered as a virtual long-term randomized
intervention study on pharmacological blockade of the
CCR5 receptor providing a fast and cheap simula-
tion setup for a real-life clinical trial. Systematic reviews
have shown that pharmacogenetic screen and treat
programmes show great potential for developing cost-
effective treatment modalities [22,23]. In this analysis,
we use these concepts to estimate the potential cost-
effectiveness of CCR5D32 screening and pharmacological
CCR5 blockade in dialysis patients, from the perspective
of the Dutch healthcare system.
Methods
Patients
For this study we used data from our previously published
study on the effect of the CCR5D32 polymorphism on
inflammation-associated mortality in dialysis patients.
This study was part of the NEtherlands COoperative
Study on the Adequacy of Dialysis (NECOSAD), a
multicenter prospective follow-up study comprising
incident (new and consecutive) ESRD patients from 38
Dutch dialysis centres included between July 1998 and
December 2001. Detailed descriptions of the study
design and results have been published previously [19].
Eligibility criteria for inclusion in the NECOSAD cohort
were 18 years or older and no previous renal replacement
therapy. All patients gave informed consent and all local
medical ethics committees gave their approval. Patients
were evaluated at 3 and 6 months after start of dialysis
and every 6 months thereafter until death or date of
censoring. Censoring involved transfer to a nonparticipat-
ing dialysis centre, withdrawal from the study or end of
the follow-up period in June 2007. Patients receiving
a kidney transplant were not censored; data on their
survival were obtained from the Dutch renal registry
(RENINE).
Data collection and clinical definitions
High-sensitivity CRP (hsCRP) was measured by means
of particle-enhanced immunonephelometry using a
standard CardioPhase hsCRP for BNII (Dade Behring
Holding GmbH, Liederbach, Germany; detection limit
0.1mg/l, precision 0.1mg/l) [24]. Systemic inflammation
was defined as hsCRP concentrations above 10mg/l. This
cutoff point has been used in ESRD patients and has
been validated with regard to the prediction of survival of
ESRD patients [25]. In addition it was demonstrated that
a single measurement of elevated CRP levels was
associated with a similar predictive power on mortality
as repeated CRP measurements [26].
CCR5 genotypes were determined with a PCR-based
allelic discrimination assay using primers (Life Techno-
logies Corporation, Carlsbad, California, USA) and
allele-specific probes (Life Technologies) as described
previously [27].
Patients were divided in four groups based on their
CCR5D32 genotype and hsCRP level: CCR5 insertion/
insertion with low hsCRP (<10mg/l), CCR5 ins/ins with
high hsCRP (>10mg/l), CCR5D32 with low hsCRP
(<10mg/l) and CCR5D32 with high hsCRP level
(> 10mg/l). Patients homozygous or heterozygous for
the deletion allele were clustered since the presence of
one minor allele has been associated with reduced receptor
function [14]. Causes of death were classified according to
the codes of the European Renal Association – European
Dialysis and Transplantation Association [28]. The follow-
ing codes were used to classify cardiovascular mortality:
myocardial ischaemia and infarction; cardiac failure, fluid
overload and pulmonary oedema, cardiac arrest, cerebro-
vascular accident, haemorrhage from ruptured vascular
aneurysm, mesenteric infarction, hyperkalaemia, hypo-
kalaemia, cause of death uncertain or unknown.
Analytical approach
We modelled the potential cost-effectiveness of CCR5D32
screening and pharmacological CCR5 blockade using
a decision-analytic Markov model (Fig. 1). Markovian
modelling is a commonly used technique in decision
analyses to handle the complexity of multiple intercon-
nective possible consequences [29]. The health states in
our Markov model were haemodialysis (HD), peritoneal
dialysis (PD), renal transplantation (Tx) and death.
Cohorts of 1000 patients entered the model in the HD
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or PD health state and were followed for a time period
of 10 years. Clinical data were used to model transition
probabilities; patients could receive a kidney transplant,
experience renal graft failure and return to dialysis or die.
The number of patients in each health state was
determined by monthly cycles throughout the entire
follow-up period [30].
Effectiveness of pharmacological CCR5 blockade
Transition probabilities for kidney Tx and mortality were
calculated using the patient-level NECOSAD data [19].
Kidney Tx and mortality rates were calculated for the
four patient groups. As of small numbers the rate of renal
transplant failure was calculated for all four groups
combined. Pharmacological CCR5 blockade was assumed
to mimic the effects of the D32 polymorphism in patients
with high inflammation status, thus, improving patient
survival in the patient group with the CCR5 insertion/
insertion genotype and systemic inflammation up to the
level of the patient group with the CCR5D32 polymorph-
ism and systemic inflammation. In particular, the relative
risk (RR) for pharmacological CCR5 blockade in the
inflamed group was calculated using clinical data as 0.61
for all-cause mortality, 0.41 for cardiovascular mortality
and 0.80 for noncardiovascular mortality. While the
main focus of this analysis was on mortality, we also
calculated, based on clinical data, that pharmacological
CCR5 blockade improved the probability of renal Tx
(RR=2.41). To reflect our main focus on mortality we
performed a separate analysis without modelling an effect
on the probability of renal Tx.
Utilities
Health-related quality of life (QoL) of patients on HD
and PD were obtained by interviewing patients partici-
pating in the NECOSAD study, detailed inclusion criteria
and methods are described elsewhere [31]. QoL of
patients in the Dutch NECOSAD study were assessed
with the EQ-5D instrument (EuroQol Group, Rotterdam,
The Netherlands), which were applied to data from a UK
population sample to obtain community based preference
data [32]. No QoL-assessment of transplanted patients
was performed in NECOSAD patients; these utilities
were obtained from a Swedish study [33]. With QoL
measurements, cost-effectiveness estimations can be
made in terms of costs per quality-adjusted life years
(QALY) gained. A commonly cited implicit threshold for
treatments that are deemed good value for money is
h50 000 per QALY in The Netherlands [34].
Costs
A third-party healthcare payer perspective was adopted
for cost estimates. Healthcare costs were classified into
one of two categories: related costs and unrelated future
costs [35].
Related costs comprise costs directly related to the
strategy under consideration. The cost of the genetic
screening test for the CCR5D32 polymorphism was based
on PCR and included staff costs [36]. The price of
hsCRP screening was based on Dutch laboratory prices.
Drug costs of pharmacological CCR5 blockade were based
on Dutch prices of the CCR5 antagonist Maraviroc
300mg (Celsentri) once daily [37], including 6% value-
added tax and a 3-monthly pharmacists’ prescription fee
of h600. Costs of cardiovascular mortality were based on
national Dutch life tables and healthcare expenditures
adjusted for comorbidities [38]. Costs of noncardio-
vascular death and of Tx graft failure were derived
from a study with data from Dutch registries on renal
diseases [39].
Fig. 1
















Decision tree and Markov model (M). Transition probabilities of the Markov model are shown in Table 2. Tx, transplantation.
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Unrelated future costs comprised costs that are indepen-
dent of current spending, apart from the effects of that
spending on survival [40,41]. In particular, as dialysis and
renal Tx care are not a direct consequence of CCR5
blockade but of the preexisting condition of ESRD; these
costs were consistently classified as unrelated future
costs. The costs of dialysis and renal Tx were based on
data on volumes of recourse use, including consultations,
hospitalisations and laboratory services and use of
medication obtained from the NECOSAD study [31].
In line with current pharmacoeconomic guidelines,
unrelated future costs were not included [35,42]. How-
ever, to determine the influence of unrelated future
costs, these costs were included in a separate analysis. All
costs were updated to 2009 values.
Discounting rates
Costs were discounted at 4% per annum and health
effects at 1.5% per annum, following Dutch guidelines for
pharmacoeconomic research [43].
Sensitivity analyses
Univariate and probabilistic sensitivity analyses and a
threshold analysis were performed. In the univariate
sensitivity analysis, all model parameters were varied by
25% to determine the main cost and effect drivers in
our model. Discount rates were varied to 0 and 3% per
annum based on recommendations by Gold et al. [44] and
Drummond et al [35]. The probabilistic sensitivity
analysis was performed according to standard methods
[29], using 10 000 iterations and included all model
parameters, except therapy costs and effectiveness of
pharmacological CCR5 blockade which were explored in a
threshold analysis. Gamma distributions were assumed
for costs and b distributions for utilities [29]. In the
absence of data on standard deviations for costs, we
assumed 25% of the mean. Uncertainty in mortality and
Tx rates was captured by nonparametric bootstrapping of
the NECOSAD data, using 10 000 iterations [45]. As
equivalence between genetic effects and associated
pharmacologic effectiveness is not a given fact [46], a
threshold analysis was performed to determine the
combined influence of drug effectiveness and treatment
costs of pharmacological CCR5 blockade on the cost-
effectiveness of the screen-and-treat strategy. The
pharmacoeconomic model and sensitivity analyses were
constructed using the statistical package R, version 2.5.1
(R Foundation, Vienna, Austria). A graph of the threshold
analysis was constructed using Sigmaplot, version 10.0
(SYSTAT Software Inc., Chicago, Illinois, USA).
Results
Study population
The study population used for modelling consisted of 413
patients. The CCR5 insertion32/deletion32 polymorph-
ism was distributed as follows: insertion/insertion: 333
(80.6%); insertion/deletion: 73 (17.7%) and deletion/
deletion: seven (1.7%). The genotype distribution did
not deviate significantly from Hardy–Weinberg equili-
brium (P=0.21). Baseline characteristics are shown in
Table 1. The patient characteristics for the different
genotype groups were similar at the start of dialysis,
except antihypertensive medication use. Patients homo-
zygous or heterozygous for the deletion allele used more
antihypertensive medications (P=0.01). From the 413
patients included, 225 (55%) had the CCR5 insertion/
insertion genotype and low hsCRP levels, 108 (26%)
the CCR5 insertion/insertion genotype and high hsCRP
levels, 55 (13%) the CCR5D32 polymorphism and low
hsCRP levels and 25 (6%) the CCR5D32 polymorphism
and high hsCRP levels.
Mortality and transplantation rates
Annual transition probabilities without CCR5 antagonist
therapy are shown in Table 2. The probability of renal Tx
was lower in the patient group with CCR5 insertion/
insertion genotype and systemic inflammation compared
with the three other patient groups. Cardiovascular and
noncardiovascular mortality was higher in the patient
group with CCR5 insertion/insertion genotype and
systemic inflammation compared with the other patient
groups. In the Markov model, pharmacological CCR5
blockade in this patient group improved survival and the
probability of renal Tx up to the level of patients with the
CCR5D32 polymorphism and systemic inflammation
(Table 2).
Table 1 Baseline characteristics
N=413
Sex: males 253 (61.3)
Age (years) 62 (50–71)
Caucasian 379 (91.8)
Haemodialysis 277 (67.1)
Peritoneal dialysis 136 (32.9)
Primary kidney disease
Diabetes mellitus 75 (18.2)
Glomerulonephritis 48 (11.6)
Renal vascular disease 76 (18.4)
Other 214 (51.8)
Cardiovascular disease 144 (34.9)





DBP (mmHg) 83 (12.8)
SBP (mmHg) 150 (25.4)
Antihypertensive medication 356 (86.2)
Lipid-lowering medication 121 (29.3)
hsCRP (mg/l) 5.1 (1.9–13.7)
hsCRP > 10 (mg/l) 133 (32.2)
Cholesterol (mmol/l) 5.0 (1.3)
Albumin (g/l) 32.5 (6.9)
Hemoglobin (g/dl) 11.0 (1.4)
GFR (ml/min) 4.2 (3.1)
Kt/V/week 2.3 (0.9)
CRP, C-reactive protein; DBP, diastolic blood pressure; GRF, glomerular filtration
rate; hsCRP, high-sensitivity CRP; SBP, systolic blood pressure.
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Cost-effectiveness
Parameters used for the analyses are shown in Table 3.
Screening for the CCR5D32 polymorphism and treating
patients with the CCR5 insertion/insertion genotype and
systemic inflammation with pharmacological CCR5
blockade resulted in an average of 0.36 life years and
0.31 QALYs gained at an expense of h8482 per patient,
compared with h1863 per patient in the nonscreen-
ing cohort (Table 4). Therefore, the incremental cost-
effectiveness ratio (ICER) of the screen and treat
strategy compared with not screening was h18 557 per
life year gained (LYG) and h21 896 per QALY gained.
Results were similar without the model assumption that
pharmacological CCR5 blockade improved patients’
probability of renal Tx, h18 494 per LYG and h24 642
per QALY gained.
As described, the unrelated future costs of dialysis and Tx
care due to improved survival were not included. The
aforementioned increased survival of 0.36 life years in the
genetically screened cohort, indeed required considerable
dialysis costs. These costs were only partly offset by a
shift towards less costly renal Tx care in these patients.
In total, additional unrelated future costs were h6720 per
patient in the screening cohort. When these costs are
included, the cost-effectiveness of the selective screen
and treat strategy rose considerably to h37 400 per LYG
and h44 127 per QALY gained, thus doubling the ICERs
for these scenarios.
Sensitivity and threshold analyses
Results of the probabilistic sensitivity analysis are shown
in Fig. 2, demonstrating the uncertainty around the cost-
effectiveness estimates of the screen and treat strategy.
The increase in cost-effectiveness as well as the
uncertainty around these estimates because of including
unrelated future costs is evident. In Fig. 2, the solid dot





Discounting rate for costs 4% [43,47]
Related costsa
Genetic screening test h50±13 [36]
CRP screening test h21±5
Drug costs Maraviroc (per year) h5057±1,264 [37]
Transplantation graft failure h4581±1,145 [39]
Cause of death




Cardiac arrest h2448±612 [38]
Cerebrovascular accident h5753±1438 [38]
Mesenteric infarction h3550±888 [38]
Hyperkalaemia h1224±306 [38]
Cause unknown or cause uncertainb h3469±867 [38]
Noncardiovascular mortality h2316±579 [39]
Unrelated future costsa
ESRD care costs
Haemodialysis year 1 h84 825±21206 [31]
Haemodialysis later years h80 482±20121 [31]
Peritoneal dialysis year 1 h65706±16 427 [31]
Peritoneal dialysis later years h60 985±15246 [31]
Transplantation year 1 h52199±13 049 [31]
Transplantation later years h10 440±2610 [31]
Health effects
Discounting rate for health effects 1.5% [43,47]
Quality of Life
Haemodialysis 0.71±0.275 [31]




See Table 1 [19]
Therapy effectiveness (relative risk)
All-cause mortality 0.61 [19]
Cardiovascular mortality 0.41 [19]
Noncardiovascular mortality 0.80 [19]
Renal transplantation 2.41 [19]
ESRD, end-stage renal disease; SD, standard deviation.
aIn the absence of data on standard deviations for costs, we assumed 25% of the mean.
bWeighted average of all cardiovascular mortality causes.
Table 2 Annual transition probabilities (95% CI) in the four CCR5D32 polymorphism and inflammation status groups without treatment
with pharmacological CCR5 blockade [19]
CCR5 insertion/insertion,







Transplantation 10.9 5.1 11.2 11.8
(8.9–13.4) (3.0–8.4) (7.4–16.8) (6.4–21.5)
Transplantation graft failure 2.2 2.2 2.2 2.2
(1.2–4.0) (1.2–4.0) (1.2–4.0) (1.2–4.0)
Cardiovascular mortality 4.3 9.5 4.1 4.0
(3.2–5.7) (6.8–13.1) (2.3–7.4) (1.5–10.3)
Noncardiovascular mortality 4.4 9.7 4.5 7.8
(3.3–5.8) (7.0–13.4) (2.6–7.8) (4.0–15.1)
CCR5, CC-chemokine receptor 5; CCR5D32, CC-chemokine receptor 5 deletion 32; CI, confidence interval.
aIn the genotyping strategy of the economic model, patients with the CCR5 insertion/insertion and high inflammation status received CCR5 antagonists; thereby
increasing transplantation rates and reducing mortality rates up to the level of patients with the CCR5D32 polymorphism and high inflammation status.
Table 4 Cost-effectiveness in the base–case analysis
Costs Life years QALY
Standard care h1863 5.71 4.36
Screen and treat strategy h8482 6.07 4.67
Screen and treat strategy
(no Tx effect)
h8460 6.07 4.63
Cost-effectiveness Cost per LYG Cost per QALY
gained
Screen and treat strategy h18 557 h21896
Screen and treat strategy
(no Tx effect)
h18 494 h24642
QALY, quality-adjusted life years; Tx, transplantation.
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denotes the base–case outcome (using the most likely
parameter estimates), whereas the inner and outer
ellipses denote the 50 and 90% probability intervals,
respectively, around this base–case estimate. Univariate
sensitivity analyses showed that the main drivers of
the cost-effectiveness of the screen and treat strategy
were the costs of pharmacological CCR5 blockade and
the effectiveness of pharmacological CCR5 blockers to
reduce mortality. The cost-effectiveness was relatively
insensitive to plausible variations of the other parameters.
These two main parameters were further explored in a
threshold analysis, shown in Fig. 3. The red line in this
figure denotes the base–case assumptions for drug
effectiveness and treatment costs. With decreasing
therapy costs and increasing therapy effectiveness, cost-
effectiveness of the screen and treat strategy improved.
With the costs of pharmacological CCR5 blockade at the
base–case level of h5057 per year or h421 per month, a
RR for all-cause mortality of 0.82 or lower would cause
the cost-effectiveness of the screen and treat strategy
to be h50 or less per QALY gained. If the costs of CCR5
blockers drop, even a modest effectiveness in reducing
inflammation-driven mortality would result in a treat-
ment strategy that is good value for money.
Discussion
This study analyzed the potential cost-effectiveness of
screening for the CCR5D32 polymorphism and selec-
tively treating dialysis patients with the CCR5 insertion/
insertion genotype and systemic inflammation with
pharmacological CCR5 blockers. It was shown that such
a strategy could be incorporated in a potentially cost-
effective genetic screen and treat program.
Observational studies in which a genetic polymorphism is
associated with a well-characterized functional phenotype
can be considered as a type of clinical trial, with
randomization at conception, referred to as Mendelian
randomization [4–6]. Following this approach, we in-
vestigated the presumption that in an analogous manner,
pharmacological CCR5 blockade could lead to better
survival in ESRD patients and estimated the cost-
effectiveness of a genetic screen and treat strategy based
on this strategy. We used data from a genetic association
study in ESRD patients. In this study an association with
better survival was found in incident dialysis patients
with systemic inflammation carrying the CCR5D32
genotype, which was replicated in a Swedish ESRD
cohort, hereby showing the robustness of these findings.
Moreover, as the number of patients in the CCR5D32
groups was small, we did in the previous study an analysis
on the two cohorts combined, leading to the same results
[19]. The presence of the CCR5D32 polymorphism,
leading to a less functional receptor [14], was used as a
naturalistic form of pharmacologically blocking the CCR5.
This approach was used recently in cholesterol ester
transfer protein inhibition, identifying alleles that lead to
reduced CETP levels and activity [48]. Other cost-
effectiveness assessments of potential pharmacologic
interventions have previously been performed, for exam-
ple in cardiovascular disease and polypill therapy [49].
Considering the ACCE (analytic validity, clinical validity,
clinical utility and ethical, legal and social issues) model
framework for enhancing the evaluation of genetic tests,
this study adds to the second C by providing cost-
effectiveness data that supports clinical utility [50,51].
A long-standing controversy in health economics is
whether unrelated future costs should be included in
cost-effectiveness analyses [40,41,52,53]. Dialysis treat-
































QALYs gained per patient
0.6 0.8 1.0
Outer ellipses: 90% CI
Baseline
Inner ellipses: 50% CI
(a, b) Cost-effectiveness of the screen and treat strategy. (a) Excluding
unrelated future costs (end-stage renal disease care costs). (b)
Including unrelated future costs. Dotted line denotes the willingness to
pay threshold for one quality-adjusted life year at h50 000 [34]. CI,
confidence interval; QALY, quality-adjusted life years.
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QALY gained [31,54]. As dialysis is required lifelong, the
cost-effectiveness of therapies in ESRD patients has
been said to be driven more by dialysis costs than by the
costs and benefits of the intervention under considera-
tion itself [55]. Our analysis confirms these earlier
findings and underscores the relevance of the debate by
calculating that inclusion of dialysis and renal transplant
care costs double the ICER of the screen and treat
strategy. Several studies in ESRD patients did not
include the future costs of ESRD care [56–58], whereas
others analysed therapies both with and without future
costs [59–61]. By excluding ESRD costs in the main
analysis but including them in a separate analysis our
results can be widely compared. The cost-effectiveness
with inclusion of future ESRD costs was comparable to
other studies focusing on systemic anticoagulation [61],
hyperphosphataemia [60], secondary hyperparathyroid-
ism [59] and anaemia [62].
In addition to adherence to guidelines for pharmacoeco-
nomic research as possible within the constraints of novel
pharmacogenetic screening programs [22], this study had
two major strengths: (i) the analyses considered hard
endpoints, mortality and renal Tx; (ii) most primary data
used in the pharmacoeconomic analysis, such as costs,
QoL estimates and efficacy data were derived from a
single prospectively followed dialysis cohort (NECO-
SAD). These strengths enhanced the clinical relevance
and analytical robustness of the study findings. Although
cost data used in this study were specific for the
Netherlands, chronic kidney disease care costs such as
dialysis costs have been reported to fall within a narrow
range despite considerable variation in country of study,
methodology and imputed costs [54]. Country-specific
variations in drug costs and discounting rates have been
accounted for in sensitivity analyses.
An important aspect of this study is the notion that
equivalence between genetic effects and associated
pharmacologic effectiveness is not a given fact. For
example, a discordance has been described between the
genetic effect of familial hypercholesterolaemia and the
effectiveness of statin treatment on cardiovascular
mortality [46]. The explanation for this discrepancy lies
in the fact that genetic factors, as opposed to pharma-
cologic interventions, cause lifelong differences in risk
factors [46]. Genetic factors are also not affected by
traditional sources of uncertainty in clinical effectiveness,
such as therapy compliance. Indeed, sensitivity analyses
showed that the cost-effectiveness was highly influenced
by the concordance between the genetic association and
pharmacological effectiveness. Nevertheless, although
the true effectiveness of pharmacological CCR5 blockade
in ESRD patients on mortality is not (yet) known, this
study, in particular the threshold analysis, provides
valuable information for future clinical trials in this field.
In this context, the threshold analysis showed that even
modest pharmacological effectiveness would result in a
treatment strategy that is good value for money. A similar
approach has recently been taken in analyzing the
potential cost-effectiveness of alternative treatments for
patients with chronic kidney disease resistant to angio-
tensin I-converting enzyme inhibitors due to angiotensin
I-converting enzyme (insertion/deletion) polymorphisms
[36]. Finally, the robustness of the cost-effectiveness

















































<    20K/QALY
<    40K/QALY
<    60K/QALY
<    80K/QALY
<    100K/QALY
Threshold analysis on the influence of CCR5 blocking therapy costs and effectiveness on the cost-effectiveness of a screen and treat strategy. The
red lines denote the base–case parameters for drug effectiveness and treatment costs. QALY, quality-adjusted life years; RR, relative risk.
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blocking CCR5 is safe in patients with ESRD. However,
treating HIV-infected patients with ESRD with a CCR5
antagonist seemed safe and no dose adjustments were
necessary [63]. The next research step could be conducting
an observational cohort study in HIV-infected patients with
ESRD, to compare cardiovascular morbidity or mortality or
surrogate endpoints such as intima media thickness, among
users and nonusers of CCR5 blocker therapy.
In conclusion, we evaluated the potential cost-effective-
ness of pharmacologically blocking the CCR5 receptor in
inflamed dialysis patient with the CCR5 insertion/inser-
tion genotype, and found it to be similar to existing
treatment modalities for dialysis patients. Recently CCR5
blockade has indeed become feasible in humans. These
data suggest that, from an economic point of view, it would
be worthwhile to study whether pharmacological blockade
of CCR5 has therapeutic and economical benefits in
dialysis patients with persistent inflammation. Our study
is an illustration of the potential of genetic studies in drug
development programs, as a new source of Mendelian
randomized evidence from an observational setting.
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